Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)

NCT02469857 is registered in ClinicalTrials.gov with Atox Bio Ltd as lead sponsor.

NCT NCT02469857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02469857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)
Lead sponsor
Atox Bio Ltd
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2015
Completion date
October 18, 2019
Enrollment
290 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

fournier's gangrene, necrotizing fasciitis, necrotizing soft tissue infections